Abstract
In 2006, panitumumab, the first fully human antibody generated from transgenic mice, was approved for clinical use by the US Food and Drug Administration (FDA). Since then, a further seven such antibodies have been approved. In this chapter, we discuss how transgenic mice technologies can provide a powerful platform for creating human therapeutic antibodies.
MeSH terms
-
Animals
-
Antibodies / genetics
-
Antibodies / metabolism*
-
Antibodies / therapeutic use*
-
Antibodies, Monoclonal, Humanized / genetics
-
Antibodies, Monoclonal, Humanized / metabolism*
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Humans
-
Immunoglobulins / genetics
-
Immunoglobulins / metabolism
-
Immunoglobulins / therapeutic use
-
Mice
-
Mice, Transgenic
-
Peptide Library*
Substances
-
Antibodies
-
Antibodies, Monoclonal, Humanized
-
Immunoglobulins
-
Peptide Library